Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

Related Content

After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

Mar 26 2012

Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus

May 14 2012

ESRD Market Snapshot: The Price Has To Be Right

May 14 2012

Hoping Drugs Take Root, Alder Raises $38 Million Round

Apr 19 2012

Allergan And MAP Team Up On Inhalable Migraine Treatment

Jan 31 2011

Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence

Jul 04 2011

NuPathe Must Patch Together New Zelrix Launch Timetable After "Complete Response" Letter

Aug 30 2011

MDD Market Snapshot: Depressing Future For Antidepressants

Aug 15 2011

Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly

Oct 19 2011

Botox For Migraine: How Will The Market Size Up?

Oct 25 2010

Related Companies

GSK plc

Merck & Co., Inc.

AstraZeneca PLC

Allergan plc

Medicis Pharmaceutical Corporation

MAP Pharmaceuticals

NuPathe, Inc.

Zogenix, Inc.

Astellas Pharma, Inc.

Aralez Pharmaceuticals Inc.

Bayer AG

Desitin Pharmaceuticals GmbH

Johnson & Johnson

Johnson & Johnson

CoLucid Pharmaceuticals, Inc.

Ariel Pharmaceuticals Inc.

BTG plc

Alder Biopharmaceuticals, Inc.

Eli Lilly and Company

Arteaus Therapeutics, LLC

Additional Topics

Europe Asia Pacific Clinical Trials Advertising, Marketing & Sales Launches Regulation BioPharmaceutical

More from Europe

More from Geography

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window